1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008. 359:1577–1589.

2. Park JY, Kim SW, Cho GY, Lee MH, Je SJ, Lee KU, Kim GS. The prevalence of micro-and macrovascular complications of korean niddm patients. J Korean Diabetes Assoc. 1993. 17:377–385.

3. Juutilainen A, Kortelainen S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care. 2004. 27:2898–2904.

4. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care. 2007. 30:292–299.

5. Rosolova H, Petrlova B, Simon J, Sifalda P, Sipova I, Sefrna F. Macrovascular and microvascular complications in type 2 diabetes patients. Vnitr Lek. 2008. 54:229–237.

6. Burt D, Bruno G, Chaturvedi N, Schalkwijk C, Stehouwer CD, Witte DR, Fuller JH, Pinach S, Cavallo Perin P, Gruden G. Anti-Heat Shock Protein 27 Antibody Levels and Diabetic Complications in the EURODIAB Study. Diabetes Care. 2009.

7. Soedamah-Muthu SS, Chaturvedi N, Pickup JC, Fuller JH. The EURODIAB Prospective Complications Study (PCS). Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. Diabetologia. 2008. 51:493–501.